The use of the calcium-binding protein S100A7, S100A8 or S100A10 as a maker for determining the sensitivity of a subject who has colorectal cancer to the anti-cancer agents oxaliplatin, cisplatin, irinotecan or SN-38.

Disclosed is a method for determining the sensitivity to irinotecan, SN-38 and/or a salt thereof, which can determine the therapeutic response of individual patients. Also disclosed is a novel means for treating cancer, which utilizes the method. Specifically disclosed is a method for determining the sensitivity to irinotecan, SN-38 and/or a salt thereof, which is characterized by measuring the expression level of AMD1 gene, CTSC gene, EIF1AX gene, C12orf30 gene, DDX54 gene, PTPN2 gene and TBX3 ...

Disclosed is an irinotecan formulation including a liposome formed by a membrane of lipid bilayer containing a phospholipid as a main membrane component, wherein only the outer surface of the liposome is modified with a surface-modifying agent containing a hydrophilic polymer, in which irinotecan and/or a salt thereof is encapsulated at a concentration of at least 0.1 mol/mol (drug mol/membrane total lipid mol) by an ion gradient between the inner aqueous phase and outer aqueous phase of the lip...

Disclosed is a method for preparing c-type crystals of irinotecan hydrochloride, including mixing irinotecan with one or more solvents selected from the group consisting of acetone, acetonitrile and tetrahydrofuran, adding hydrochloric acid, and collecting the formed crystals.

A process for preparing 2'-amino-5'hydroxypropiophenone to synthesize camptothecin analogs as depicted in the diagram as disclosed, where R is a protective group which can be deprotected by a catalytic reduction. Camptothecin analogs such as 7-ethyl-10-hydroxycamptothecin are key intermediates in synthesis of irinotecan, a type of anti-cancer topoisomerase inhibitor. (62) Divided out of 527615